Research programme: inhaled dry powder respiratory therapeutics - MicroDose Therapeutx

Drug Profile

Research programme: inhaled dry powder respiratory therapeutics - MicroDose Therapeutx

Latest Information Update: 23 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer MicroDose Therapeutx
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Respiratory tract disorders

Most Recent Events

  • 23 Sep 2014 Discontinued for Respiratory tract disorders (Inhalation)
  • 08 Jul 2013 MicroDose Therapeutx has been acquired by Teva Pharmaceutical Industries
  • 01 Dec 2011 No development reported for Respiratory tract disorders (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top